Private equity firm Symphony Technology Group has acquired a majority ownership interest in ImpactRx, leaving Merck Capital Ventures, the corporate venturing unit of US-based drugs group Merck, a shareholder.
The corporate venturing investor in ImpactRx, a US-based data provider to doctors, has remained a minority shareholder after the sale of the portfolio company to provide a return to its venture capital backers.
Private equity firm Symphony Technology Group (STG) has acquired a majority ownership interest in ImpactRx, leaving Merck Capital Ventures, the corporate venturing unit of US-based drugs group Merck, a shareholder.
The venture capital (VC) firms that sold out include Mediphase Venture Partners and Oxford Bioscience Partners and…
